Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Go back to Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Harmony Metals, Inc. Common (NASDAQ: HRMY) Delayed: 36.13 +0.10 (0.28%)
Previous Close $36.03    52 Week High $1.35 
Open $36.11    52 Week Low $0.10 
Day High $37.05    P/E N/A 
Day Low $35.00    EPS $0.00 
Volume 2,313,566